Table 1 Absolute leukocyte counts in the... | American Society of Hematology

Table 1

Absolute leukocyte counts in the blood increase in response to treatment with long-term low-dose plerixafor therapy

Cell type	Cells per microliter of blood (mean ± SEM)
Cell type	Baseline*	Peak plerixafor†	Reference range‡
CD4⁺ T cells	206 ± 71	1498 ± 186§	359-1565
CD4⁺CD45RA⁺ naive T cells	49 ± 29	201 ± 6§	454-733
CD4⁺CD45RA^– memory T cells	157 ± 45	1297 ± 192§	216-1048
CD4⁺CD45RA^–CD62L⁺CCR7⁺ central memory T cells	1 ± 0.5	14 ± 9	16-49
CD4⁺CD45RA^–CD62L^–CCR7^– effector memory T cells	99 ± 16	603 ± 107	57-130
CD8⁺ T cells	111 ± 31	502 ± 124	178-853
CD8⁺CD45RA⁺ naive T cells	64 ± 27	233 ± 51§	231-371
CD8⁺CD45RA^– memory T cells	47 ± 4	269 ± 74	50-352
CD8⁺CD45RA^–CD62L⁺CCR7⁺ central memory T cells	<1	<1	0-12
CD8⁺CD45RA^–CD62L^–CCR7^– effector memory T cells	32 ± 5	176 ± 57	22-75
CD3^–CD56⁺ NK cells	80 ± 6	151 ± 43	126-729
CD19⁺ B cells	19 ± 5	160 ± 103	61-329
CD19⁺CD27⁺ memory B cells	1.5 ± 0.7	6 ± 2	18-29
CD19⁺CD27^– B cells	11 ± 4	155 ± 102	90-176
CD19⁺CD27^–IgD⁺IgM⁺ transitional B cells	8 ± 5	98 ± 56	42-85
CD19⁺CD27^–IgD^–IgM⁺ immature B cells	<1	1 ± 0.1	2-10
CD14⁺ monocytes	70 ± 6	273 ± 67	240-860
CD14⁺CD16^– classical monocytes	65 ± 5	250 ± 64	371-539
CD14⁺CD16⁺ inflammatory monocytes	5 ± 1	24 ± 9	14-30

Cell type	Cells per microliter of blood (mean ± SEM)
Cell type	Baseline*	Peak plerixafor†	Reference range‡
CD4⁺ T cells	206 ± 71	1498 ± 186§	359-1565
CD4⁺CD45RA⁺ naive T cells	49 ± 29	201 ± 6§	454-733
CD4⁺CD45RA^– memory T cells	157 ± 45	1297 ± 192§	216-1048
CD4⁺CD45RA^–CD62L⁺CCR7⁺ central memory T cells	1 ± 0.5	14 ± 9	16-49
CD4⁺CD45RA^–CD62L^–CCR7^– effector memory T cells	99 ± 16	603 ± 107	57-130
CD8⁺ T cells	111 ± 31	502 ± 124	178-853
CD8⁺CD45RA⁺ naive T cells	64 ± 27	233 ± 51§	231-371
CD8⁺CD45RA^– memory T cells	47 ± 4	269 ± 74	50-352
CD8⁺CD45RA^–CD62L⁺CCR7⁺ central memory T cells	<1	<1	0-12
CD8⁺CD45RA^–CD62L^–CCR7^– effector memory T cells	32 ± 5	176 ± 57	22-75
CD3^–CD56⁺ NK cells	80 ± 6	151 ± 43	126-729
CD19⁺ B cells	19 ± 5	160 ± 103	61-329
CD19⁺CD27⁺ memory B cells	1.5 ± 0.7	6 ± 2	18-29
CD19⁺CD27^– B cells	11 ± 4	155 ± 102	90-176
CD19⁺CD27^–IgD⁺IgM⁺ transitional B cells	8 ± 5	98 ± 56	42-85
CD19⁺CD27^–IgD^–IgM⁺ immature B cells	<1	1 ± 0.1	2-10
CD14⁺ monocytes	70 ± 6	273 ± 67	240-860
CD14⁺CD16^– classical monocytes	65 ± 5	250 ± 64	371-539
CD14⁺CD16⁺ inflammatory monocytes	5 ± 1	24 ± 9	14-30

CD, cluster of differentiation; NK, natural killer; SEM, standard error of the mean.

Baseline values were established before the study began off G-CSF.

Peak plerixaflor refers to blood counts measured 3 hours after a morning dose during the 6th month of treatment.

Reference range values were established from 12 to 40 healthy volunteers not receiving either plerixafor or G-CSF.

P < .05.